- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03411252
Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study
March 22, 2021 updated by: Jeff GI, Thomas Jefferson University
This study evaluates whether a medication called mirabegron is better than placebo (sugar pill) in helping patients with achalasia swallow better.
Each patient will receive either mirabegron or the placebo for 4 weeks followed by the opposite medication.
Each patient will complete several surveys and undergo several tests to determine if the mirabegron is helping reduce the pressures in the esophagus (swallowing tube).
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Achalasia is characterized by incomplete or absent relaxation of the lower esophageal sphincter (LES) and loss of esophageal peristalsis which leads to dysphagia.
Standard of care for achalasia includes endoscopic management (dilation and injection of injection of botulinum toxin) and surgery, however both of these options carry procedural risks, may lose efficacy over time and many patients are not appropriate candidates for these treatment options.
Unfortunately, there are limited oral medications for patients with achalasia.
Mirabegron is an oral beta-3 agonist currently FDA approved for overactive bladder that works by relaxing the bladder muscles.
Beta-3 receptors have also been identified in the LES with stimulation leading to LES relaxation in preclinical studies.
Through a proof of concept pilot study, the investigators aim to evaluate the effect of mirabegron in patients with achalasia via high resolution manometry and a validated dysphagia scale.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years old < Age < 75 years old with prior diagnosis of achalasia via manometry and/or radiographically
Exclusion Criteria:
- < 18 years old or > 75 years old
- History of hypertension not controlled on oral medications (blood pressure > 160/100 mm Hg)
- No prior history of hypertension with a blood pressure > 160/100 mm Hg
- History of bladder outlet obstruction
- History of angioedema
- Pregnant or breast-feeding women: Women between 18 and 40 years old who are enrolled in the study will be required to use a form of birth control during the study
- Patients currently receiving certain medications (digoxin, warfarin, any overactive bladder medications, thioridazine, flecainide, propafenone, phosphodiesterase inhibitors)
Patients with prolonged QTc interval or risk factors to develop it:
- Baseline QTc on EKG of > 450 milliseconds
- History of additional risk factors for Torsades de Pointes (heart failure, family history of long QT syndrome)
- Concomitant medications that prolong the QTc interval: ranolazine, sotalol, dofetilide, procainamide, disopyramide, propafenone, azole antifungals, fluoroquinolones, macrolide antibiotics, HIV antiretrovirals, chemotherapy, beta-2 agonists, tricyclic antidepressants, selective serotonin reuptake inhibitors
- Prior surgeries for achalasia
- < 2 months since last endoscopic botulinum toxin injection into LES or endoscopic dilation
- Stage 4 Chronic kidney disease (severe renal impairment with GFR 15-29 ml/min), Stage 5 Chronic Kidney disease (GFR < 15 ml/min or on dialysis)
- Childs Pugh B (moderate) or C (severe) Cirrhotic (hepatic impairment)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mirabegron
Patients will receive 50 mg of oral Mirabegron daily for 4 weeks and then switch to placebo by mouth daily for an additional 4 weeks.
|
Myrbetriq (Mirabegron) tablet
Other Names:
Sugar pill manufactured to mimic Mirabegron
Other Names:
|
Placebo Comparator: Placebo
Patients will receive placebo by mouth daily for 4 weeks and then switch to oral Mirabegron 50 mg daily for an additional 4 weeks.
|
Myrbetriq (Mirabegron) tablet
Other Names:
Sugar pill manufactured to mimic Mirabegron
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in lower esophageal sphincter pressures
Time Frame: Change in lower esophageal sphincter pressure from baseline after 4 weeks of placebo or Mirabegron
|
Evaluation of changes in lower esophageal sphincter pressures using high resolution manometry
|
Change in lower esophageal sphincter pressure from baseline after 4 weeks of placebo or Mirabegron
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Eckardt Achalasia Score (EAS)
Time Frame: Patients will complete the EAS on study day -14, 0, 7, 28, 42, 49, 70, 84. We will evaluate changes in patient's EAS between day 0 and all of these time points.
|
Patients will complete the Eckardt Achalasia score which is a simple written scale evaluating dysphagia, regurgitation, retrosternal pain and weight loss.
Patients report their symptoms from a 0 to 3. Weight loss (0-none, 1: < 5 kg, 2: 5-10 kg, 3: > 10 kg), Dysphagia (0-none, 1-occasional, 2-daily, 3-each meal), Retrosternal pain (0-none, 1-occasional, 2-daily, 3-each meal), Regurgitation (0-none, 1-occasional, 2-daily, 3-each meal).
The value for each of the 4 categories is added together to give the EAS.
This EAS will be reported for each time point below.
A higher score is consistent with worse achalasia and worse outcomes.
A lower score is consistent with less severe achalasia and better outcomes.
The total range is 0 (no symptoms) to 12 (severe symptoms).
There are no subscales.
|
Patients will complete the EAS on study day -14, 0, 7, 28, 42, 49, 70, 84. We will evaluate changes in patient's EAS between day 0 and all of these time points.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 15, 2018
Primary Completion (Actual)
December 15, 2019
Study Completion (Actual)
December 15, 2019
Study Registration Dates
First Submitted
December 11, 2017
First Submitted That Met QC Criteria
January 18, 2018
First Posted (Actual)
January 26, 2018
Study Record Updates
Last Update Posted (Actual)
March 24, 2021
Last Update Submitted That Met QC Criteria
March 22, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Esophageal Achalasia
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Adrenergic Agonists
- Adrenergic beta-Agonists
- Adrenergic beta-3 Receptor Agonists
- Mirabegron
Other Study ID Numbers
- 17P.054
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Achalasia
-
Zeng ChanghaoRecruitingCricopharyngeal AchalasiaTaiwan
-
Copka SonpashanNot yet recruitingCricopharyngeal Achalasia
-
Germans Trias i Pujol HospitalActive, not recruiting
-
Govind Ballabh Pant HospitalActive, not recruitingAchalasia CardiaIndia
-
Asian Institute of Gastroenterology, IndiaUnknown
-
University Hospital, Strasbourg, FranceCompleted
-
Hospices Civils de LyonCompleted
-
Cairo UniversityRecruitingAchalasia | Achalasia CardiaEgypt
-
Mayo ClinicTerminatedAchalasia | Esophageal Achalasia | Achalasia, EsophagealUnited States
-
Federico II UniversityCompleted
Clinical Trials on Mirabegron 50 MG
-
Genuine Research Center, EgyptHikma PharmaCompleted
-
Astellas Pharma Europe Ltd.CompletedUrologic Diseases | Urinary Bladder Diseases | Urinary Bladder OveractiveUnited States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
-
The Affiliated Ganzhou Hospital of Nanchang UniversityActive, not recruiting
-
Cedars-Sinai Medical CenterRecruitingSyncope | Postural Orthostatic Tachycardia Syndrome | Chronic Orthostatic IntoleranceUnited States
-
Chang Gung Memorial HospitalCompletedUrinary Bladder, Overactive | Sexual Behavior | Sexual Function Disturbances | Behavior Therapy | Sexual ActivityTaiwan
-
University Hospitals Cleveland Medical CenterWithdrawnOveractive BladderUnited States
-
University of Alabama at BirminghamCompletedOveractive BladderUnited States
-
Zydus Lifesciences LimitedRecruitingAmyotrophic Lateral SclerosisIndia
-
Chang Gung Memorial HospitalUnknownOveractive Bladder Syndrome | Detrusor Overactivity
-
Shachi TyagiNational Institute on Aging (NIA)RecruitingNocturia | Urgency Urinary IncontinenceUnited States